genprowebdirectory
News
Insights
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Supplement
Resources
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
News
News
Biogen Shares Surge after Reversal on Alzheimer’s Candidate Aducanumab
Autoimmune Disease Drugs
Takeda Licenses COUR’s Celiac Disease Candidate after Successful Phase IIa Trial
Cell Analysis
Cell Stiffness May Indicate Likelihood of Cancer Metastasis
News
Creatine Arms T Cells for the Battle against Cancer
Artificial Intelligence
Synthetic Biologists Develop an Ear for the Language of Proteins
Insights
Insights
Top 10 Asia Biopharma Clusters 2019
Tech Exclusives
Genome Editing Heads to Primetime
On Your Radar
From Poetry to Policy: An Interview with Bartha Maria Knoppers
Commentary
Successfully Addressing the Challenges of Glycosylation
Brexit
Top 10 European Biopharma Clusters
A-Lists
Insights
Top 10 Asia Biopharma Clusters 2019
Brexit
Top 10 European Biopharma Clusters
Insights
Top 10 U.S. Biopharma Clusters
Insights
10 Takeover Targets to Watch This Fall
Insights
What the Top 10 Biopharma CEOs Are Making
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
News
Biogen Shares Surge after Reversal on Alzheimer’s Candidate Aducanumab
Bioprocessing
Process Guidance: Cellvento® 4CHO Fed-batch Medium
Autoimmune Disease Drugs
Takeda Licenses COUR’s Celiac Disease Candidate after Successful Phase IIa Trial
Cell Analysis
Cell Stiffness May Indicate Likelihood of Cancer Metastasis
Magazine
All
Supplement
October 2019 Vol. 39 No. 10
Better Living through Molecular Neuropharmacology
October 2019 Vol. 39 No. 10
CRISPR Dx May Help Nix Disease
Tech Exclusives
Modular Bioprocessing Makes Adaptability a Snap
Tech Exclusives
A Nanomedicine Technology Sampler Pack
Resources
All
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
GENcast
Vaccinating the World One Collaboration at a Time
eBooks
Better Research Begins with an Experienced Solution Provider
Upcoming Webinars
A Cultured Life: Innovations in Spheroid and Organoid Models
Posters
Microfluidic Diffusional Sizing: A Novel Method for Characterizing Protein Interactions
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Home
Therapeutics
Autoimmune Disease Drugs
Autoimmune Disease Drugs
Most popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Autoimmune Disease Drugs
New Work Opens Door to Manipulating Aberrant Calcium Signaling in Immune System
Autoimmune Disease Drugs
GSK Invests $300M in 23andMe as Companies Collaborate on Drug Development
Autoimmune Disease Drugs
GSK Ends Effort to Commercialize Basilea’s Eczema Drug in U.S.
Autoimmune Disease Drugs
Critical Cellular Player Controlling HIV Reproduction in Immune Cells Identified
Autoimmune Disease Drugs
Technique Converts Harmful Autoantibodies into Anti-Inflammatory Antibodies In Vivo
Autoimmune Disease Drugs
Top 10 GEN News Articles of 2018
Autoimmune Disease Drugs
Novartis’ Sandoz Buys European Rights to Biosimilar Remicade
Autoimmune Disease Drugs
Takeda Licenses COUR’s Celiac Disease Candidate after Successful Phase IIa Trial
Autoimmune Disease Drugs
Immune Disorder Trigger Identified
Autoimmune Disease Drugs
argenx Plans Autoimmune Treatments Using Halozyme’s ENHANZE Drug-Delivery Technology
Autoimmune Disease Drugs
Lupus: Scientists Uncover Why Some Immune Cells Go Rogue
Autoimmune Disease Drugs
Testosterone-Activated Anti-MS Mechanism Could Protect Women
Autoimmune Disease Drugs
Alexion Inks Collaborations Totaling $1.3B+ with Affibody, Zealand
Autoimmune Disease Drugs
Immunotherapy Slashes Rheumatoid-Associated Heart Disease Risk
Autoimmune Disease Drugs
With $250M in Financing, AstraZeneca Spinout to Focus on Severe Autoimmune...
1
2
3
Page 1 of 3
Scroll Up
Please wait while you are redirected to the right page...
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![This confocal microscopic image of a healthy mouse T cell uses color florescence to illustrate how the protein Gimap5 (upper-right faint green area) and the enzyme GSK3 (red) overlap in small structures called vesicles inside cells (colocalized yellow area). This happens before GSK3 enters the cell nucleus (shown in blue). This step is important to limit DNA damage in active T cells during their expansion. The image is part of a study published Jan. 30 by Nature Communications from researchers at Cincinnati Children's. [Cincinnati Children's]](https://www.genengnews.com/wp-content/uploads/2018/08/Jan30_2018_CincinnatiChildrens_TCellRegulator1019210011-324x160.jpg "Immune Disorder Trigger Identified")
![GlaxoSmithKline (GSK) has made a $300 million equity investment in 23andMe under a collaboration designed to accelerate development of new therapies for both companies by using genetic data to identify new drug targets. [Source: © fotoliaxrender/Fotolia]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug5_2014_56448122_DNAblue_NovelDiagnosticGenomic12114111424-265x198.jpg "GSK Invests $300M in 23andMe as Companies Collaborate on Drug Development")
